Company intelligence / Profile preview
Phrontline Biopharma
Shanghai, Shanghai, Chinaphrontlinebio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Phrontline Biopharma’s lead product, TJ101 (a bispecific ADC), is currently in IND-enabling studies. The company has developed proprietary dual-payload and dual-targeting platforms to address drug resistance and improve efficacy in oncology. No clinical results have been reported yet as all programs are preclinical.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs), including bispecific ADCs and dual-payload ADCs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Member of Roche Accelerator programseeking partners for unlicensed products such as TJ101 and TJ102
Beyond the preview
Go deeper on Phrontline Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phrontline Biopharma.